Takeda Receives FDA Approval for Brigatinib
Takeda Pharmaceutical Company Limited (TAK) announced that the FDA has given a green signal for its ALUNBRIG (Brigatinib) in adult patients suffering from anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer. The label expansion allows the drug to be used in first line setting.
The FDA approval is based on the data obtained from Phase 3 ALTA 1L trial, which aimed to assess the safety and efficacy of ALUNBRIG compared to crizotinib in adult patients. The participants had ALK+ locally advanced or metastatic NSCLC who have